[{"id":"9b184044-2e16-4963-ad5a-81b4952b2240","acronym":"FIERCE-HN","url":"https://clinicaltrials.gov/study/NCT06064877","created_at":"2023-10-03T19:11:25.933Z","updated_at":"2024-07-02T16:34:59.243Z","phase":"Phase 3","brief_title":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06064877 - FIERCE-HN","lead_sponsor":"AVEO Pharmaceuticals, Inc.","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • ficlatuzumab (AV-299)"],"overall_status":"Recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 01/11/2024","start_date":" 01/11/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-06-04"},{"id":"4cac8cfd-eacc-4f31-936f-dfb51beed513","acronym":"P30CA023074","url":"https://clinicaltrials.gov/study/NCT03422536","created_at":"2021-01-18T16:53:06.344Z","updated_at":"2024-07-02T16:35:42.620Z","phase":"Phase 2","brief_title":"Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT03422536 - P30CA023074","lead_sponsor":"University of Arizona","biomarkers":" CD27","pipe":" | ","alterations":" EGFR mutation • PIK3CA mutation","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • ficlatuzumab (AV-299)"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 12/05/2017","start_date":" 12/05/2017","primary_txt":" Primary completion: 03/29/2022","primary_completion_date":" 03/29/2022","study_txt":" Completion: 04/05/2022","study_completion_date":" 04/05/2022","last_update_posted":"2023-07-19"},{"id":"27869c38-4b33-453c-b7af-d6f1b195f5d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02277197","created_at":"2021-01-18T10:43:04.747Z","updated_at":"2024-07-02T16:37:00.414Z","phase":"Phase 1b","brief_title":"Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)","source_id_and_acronym":"NCT02277197","lead_sponsor":"James J Lee","biomarkers":" MET","pipe":" | ","alterations":" MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • ficlatuzumab (AV-299)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2019-04-18"}]